MedTrace Logo

Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196

NCT03220165 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2017-12-19

No results posted yet for this study

Summary

The purpose of this study is determine in healthy males how MGL-3196 is metabolized using a radio-labeled version of MGL-3196.

Conditions

  • Healthy

Interventions

DRUG

MGL-3196

oral, 100 mg

Sponsors & Collaborators

  • Worldwide Clinical Trials

    collaborator OTHER

  • Madrigal Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • George Ate, MD · Worldwide Clinical Trials

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-06
Primary Completion
2017-09-03
Completion
2017-09-03
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03220165 on ClinicalTrials.gov